Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07023445 · ClinicalTrials.gov registry record
Patterns of Inclisiran Use in the Real World: An Analysis of US Databases
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 37,688
- Enrollment target
NCT07023445: Completed study, sponsored by Novartis Pharmaceuticals.
NCT07023445 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 37,688 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07023445 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 37,688 participants
- Enrollment target
Study Summary
This was a retrospective observational cohort study of patients who initiated inclisiran, alirocumab, or evolocumab in a real-world setting in the United States. The study used data extracted from three databases: (1) open and closed claims from Komodo's Healthcare map and electronic medical records (EMRs) from outpatient clinics affiliated with (2) Healix and (3) Metro Infusion Centers. The study period spanned from 01 January 2021 to the latest date of the available data for each database. Index date was defined as the date of the first claim for inclisiran, alirocumab, or evolocumab within the patient identification period. The 12-month period prior to the index date (including the index date) was the baseline period. Follow-up spanned from the index date up to patient disenrollment, death, or the end of the study period, whichever came first.
Primary Outcome
Demographics included: * Age group * Gender * Insurance type * Race/ethnicity
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37,688 participants |
| Start Date | 2023-01-20 |
| Est. Completion | 2024-06-28 |
What the finished NCT07023445 record still lists
NCT07023445 is an observational study that tracks outcomes without assigning an intervention. Its 37,688 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT07023445 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07023445 about?
NCT07023445 is a clinical study titled "Patterns of Inclisiran Use in the Real World: An Analysis of US Databases". This was a retrospective observational cohort study of patients who initiated inclisiran, alirocumab, or evolocumab in a real-world setting in the United States. The study used data extracted from three databases: (1) open and closed claims from Komodo's Healthcare map and electronic medical records...
What is the current status of trial NCT07023445?
This trial is currently completed. The enrollment target is 37,688 participants. The study started on 2023-01-20. Estimated completion is 2024-06-28.
Who is sponsoring clinical trial NCT07023445?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05796505 · 37,122 participants · NA
Addressing Vaccine Acceptance in Carceral Settings Through Community Engagement
- NCT07150923 · 36,503 participants · NA
Supraglottic Airway for Resuscitation Trial
- NCT03262259 · 36,000 participants · NA
Evaluation of Global Smart Drinking Goals Initiative
- NCT01255748 · 40,000 participants
Registry Study for Radiation Therapy Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI